Highlights Shuttle Pharmaceuticals Holdings, Inc.

Equities

SHPH

US8256932034

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
0.43 ^USD	+5.63%		+10.54%	-5.49%

Mar. 21	Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 08	Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma	Jan. 08	CI
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	Dec. 11	CI
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	23-09-25	CI
Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor Platform	23-09-11	CI
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient for Use in Clinical Trial	23-08-03	CI
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Shuttle Pharmaceuticals, Georgetown University Sign Research Deal to Evaluate Anti-Tumor Candidates	23-03-22	MT
Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update	23-03-16	AQ
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-15	AQ
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial	23-03-10	AQ
Shuttle Pharmaceuticals Signs Ropidoxuridine Manufacturing Deal With University of Iowa Pharmaceuticals	23-03-09	MT
Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities	23-02-23	PR
Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities	23-02-23	CI
Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31	23-01-26	PR
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023	23-01-17	PR
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants	23-01-12	PR
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications	23-01-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shuttle Pharmaceuticals Holdings, Inc.

Equities

SHPH

US8256932034

Highlights

Filters